团队现有博士后两名（均获批上海市超级博士后），博士生五名、硕士生四名，联合培养博士生三名。

研究方向：

研究组致力于白血病等恶性疾病的靶向和免疫治疗相关促降解新靶点发现和首创型靶向降解剂研发，目前主要研究方向包括：

1.    白血病等恶性疾病中致病蛋白促降解新靶点去泛素化酶 (DUB) 和泛素化酶（E3）及其配体的发现；

2.    克服多种耐药、突变选择型治疗新靶点及药物的发现；

3.    免疫治疗新靶点、小分子免疫调节剂和肿瘤免疫联合疗法的开发。

本课题组常年招聘副研究员、助理研究员、博士后数名（免疫学及药理药化研究方向优先），欢迎博士生、硕士生、本科生报考和实习！

2023年夏，杨老师带学生做SITP项目~

2023年9月，第一个教师节~~团队又壮大啦~

2023年秋，课题组团建留影~~

2024年9月，第二个教师节留影~

课题组在研主持国家自然科学基金两项，课题组长入选主持上海领军人才（海外）项目，中国科学院青促会人才计划，安徽省 "百人计划” 青年项目，并主持前沿科学中心科技领军人才团队项目，参与国家重点研发项目等。

在研主持项目：

(1) 国家自然科学基金委员会，面上项目，82373937，针对继发性急性髓系白血病中JAK2-V617F突变体的促降解新靶点发现和机制研究，2024-01-01 至 2027-12-31, 48万元, 在研, 主持

(2) 国家自然科学基金委员会, 青年科学基金项目, 82104198, 针对弥漫大B细胞淋巴瘤中EZH2-Y641突变体选择性降解剂的发现及机制研究, 2022-01-01 至 2024-12-31, 30万元, 在研, 主持

(3) 中国科学院, 中国科学院基金项目, 2022453, 青年创新促进会会员-杨静, 2022-01 至 2025-12, 80万元, 在研, 主持

(4) 上海市委, 人才项目, 上海领军人才（海外）, 2022-09 至 2025-09, 120万元, 在研, 主持

(5) 安徽省委, 安徽省海外引才计划, 安徽省“百人计划“青年项目（安徽省海外引才计划青年项目）, 2022-06 至 2025-06, 30万元, 在研, 主持

(6) 教育部前沿科学中心，前沿科学中心科技领军人才团队项目，2023-08 至 2023-11, 15万元, 在研, 主持

泛素化蛋白降解是有望突破传统抑制剂瓶颈的新策略。本课题组长期致力于泛素化表观遗传相关免疫调节新靶点和首创型降解剂、小分子免疫调节剂的研发，主要原创成果包括：①鉴定了首个和多个针对难成药转录因子RORγt、FOXP3a等的促降解去泛素化酶DUB和泛素化酶E3并开发了降解剂和免疫调节剂；②发现了首个克服白血病中FLT3-ITD复杂耐药性的促降解靶点USP10并开发了首创型降解剂；③开发并优化了首个和多个靶向血液肿瘤中组成型激活JAK2和EZH2突变等的选择性降解剂和双功能抑制剂。成果拓展了可降解蛋白组，为解决泛抑制剂耐药性和安全性问题提供新策略。以第一或通讯作者（含共同）发表Nat Chem Biol，Leukemia（两篇），STTT，EMBO Rep等论文14篇，申请专利四项，受Nat Rev Drug Discov等专刊或亮点点评。

部分代表性工作：

1.     Yushan Huang*, Jun Long*, Changpeng Yang, Wang Lu, Husheng Mei, Wenbin Qian#, Jing Yang#, Aibin Liang#. Overcoming Challenges in CAR-T Therapy for Malignancies: Mechanisms and Strategies. Clinical and Translational Discovery. 2025 (In press)

2.     Guiming Li*, Wenjun Zhang#, Jing Yang#. Time - the fourth dimension of immune cells. MedComm. 2024 Aug 4;5(8):e682.  

3.     Yiying Xue*, Husheng Mei*, Yisa Chen, James D. Griffin, Qingsong Liu#, Ellen Weisberg#, Jing Yang#. Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS-COV-2. MedComm. May 2023; 4(3):e254. 

4.     Yisa Chen, Yiying Xue, Jing Yang#. Gilteritinib: Repurposing of AXL-targeting kinase inhibitors against COVID-19. Journal of Medical Virology, Mar. 2023; 95(3):e28592. 

5.     Husheng Mei*, Hong Wu*, Jing Yang*, Bin Zhou*, Aoli Wang, Chen Hu, Shuang Qi, Zongru Jiang, Fengming Zou, Beilei Wang, Feiyang Liu, Yongfei Chen, Zuowei Wang, Wenchao Wang, Jing Liu, Qingsong Liu. Discovery of IHMT-337 as a potent irreversible inhibitor targeting novel noncanonical role of EZH2 for triple-negative breast cancer. Signal Transduct. Target Ther., 8 (1), 18, Jan. 2023.

6.     Jing Yang*, Ellen L. Weisberg*, Shuang Qi*, Wei Ni, Husheng Mei, Zuowei Wang, Chengcheng Meng, Shengzhe Zhang, Mingqi Hou, Ziping Qi, Aoli Wang, Yunyun Jiang, Zongru Jiang, Tao Huang, Qingwang Liu, Robert S. Magin, Laura Doherty, Wenchao Wang, Jing Liu, Sara J. Buhrlage, Qingsong Liu, James D. Griffin. Inhibition of deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2. Leukemia. 36, pages 1048-1057, Apr. 2022

7.     Jing Yang*, Ellen L. Weisberg*, Xiaoxi Liu*, Robert Magin, Wai Cheung Chan, Bin Hu, Nathan Schauer, Shengzhe Zhang, Ilaria Lamberto, Laura Doherty, Chengcheng Meng, Martin Sattler, Lucia Cabal-Hierro, Eric Winer, Richard Stone, Jarrod Marto, James Griffin, and Sara Buhrlage. Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2. Leukemia. 36, pages 210-220, Jan. 2022

8.     Jing Yang*, Ping Wei*, Joseph Barbi, Qianru Huang, Evan Yang, Yakun Bai, Jia Nie, Yanhang Gao, Jinhui Tao, Ying Lu, Chichu Xie, Xiaoxia Hou, Jiazi Ren, Xingmei Wu, Jian Meng, Ying Zhang, Juan Fu, Wei Kou, Yayi Gao, Zuojia Chen, Rui Liang, Andy Tsun, Dan Li, Wenzhi Guo, Shuijun Zhang, Song-Guo Zheng, Junqi Niu, Paul Galardy, Xuemei Tong, Guochao Shi, Huabin Li, Fan Pan and Bin Li. The deubiquitinase USP44 promotes Treg function during inflammation by preventing FOXP3 degradation. EMBO Reports. 21 (9), e50308, Jul. 2020

9.     Jing Yang*, Chengcheng Meng*, Ellen L. Weisberg*, Ilaria Lamberto, Martin Sattler, Nathanael S. Gray, Sara J. Buhrlage, James D. Griffin. Inhibition of the deubiquitinase USP10 induces degradation of SYK. British Journal of Cancer, 122 (8), 1175-1184. Feb. 2020

10.  Ellen L. Weisberg*, Nathan J. Schauer*, Jing Yang*, Ilaria Lamberto*, Laura Doherty, Shruti Bhatt, Atsushi Nonami, Chengcheng Meng, Anthony Letai, Renee Wright, Hong Tiv, Prafulla C. Gokhale, Maria Stella Ritorto, Virginia De Cesar, Matthias Trost, Alexandra Christodoulou, Amanda Christie, David M. Weinstock, Sophia Adamia, Richard Stone, Dharminder Chauhan, Kenneth C. Anderson, Hyuk-Soo Seo, Sirano Dhe-Paganon, Martin Sattler, Nathanael S. Gray, James D. Griffin, Sara J. Buhrlage. Inhibition of USP10 induces degradation of oncogenic FLT3. Nature Chemical Biology. 13 (12), 1207-1215. Dec. 2017 

11.  Jing Yang*#, Ellen L. Weisberg. HSP70 and FLT3-ITD: targeting chaperone system to overcome drug resistance. Blood Science. 3 (04), 151-153, Oct. 2021 (#Corresponding author)

12.  Jing Yang*, Peng Xu*, Lei Han*, Zhixiang Guo, Xiuwen Wang, Zuojia Chen, Jia Nie, Shuying Yin, Miranda Piccioni, Andy Tsun, Ling Lv, Shenglin Ge and Bin Li. Cutting Edge: Ubiquitin-Specific Protease 4 Promotes Th17 Cell Function under Inflammation by Deubiquitinating and Stabilizing RORγt. The Journal of Immunology. Mar. 2015. pii: 1401451 

13.  Xiuwen Wang*, Jing Yang*, Lei Han, Kaixia Zhao, Qingsi Wu, Zhiyuan Li, Ling Lv and Bin Li. TRAF5 Mediated K63-linked Polyubiquitination Plays an Essential Role in the Positive regulation of RORγt on promoting IL-17A Expression. Journal of Biological Chemistry. October 2015. M115.664573

14.  Lei Han*, Jing Yang*, Xiuwen Wang, Shuying Yin, Zhiyuan Li, Jing Zhang, Yue Xing, Zuojia Chen, Andy Tsun, Dan Li, Miranda Piccioni, Yu Zhang, Qiang Guo, Lindi Jiang, Liming Bao, Ling Lv and Bin Li. The E3 deubiquitinase USP17 is a positive regulator of retinoic acid-related orphan nuclear receptor γt (RORγt) in Th17 cells. Journal of Biological Chemistry. 2014 Sep. 12;289(37):25546-55.

专利：

1. 噻唑类化合物、去SUMO 和/或去泛素化酶抑制剂及其制备方法和应用 (202411569260.0)

发明人：杨静（YANG, Jing）, 梁爱斌(LIANG, AIbin), 梅沪生(Mei,Husheng), 文武强(Wen Wuqiang)

 2. Small molecule inhibition of deubiquitinating enzyme josephin domain containing 1 (Josd1) as a targeted therapy for leukemias with mutant janus kinase 2 (Jak2). (WO2023009982A1, US20240335427A1)

Sara Buhrlage, James Griffin, Ellen Weisberg, Jing Yang, Xiaoxi Liu, Robert Magin, Bin Hu, Wai Cheung Chan

 3. Use of Ubiquitination Pathway-related Factors in Regulating Function of T Helper Cell. 泛素化途径相关因子在调控辅助性T细胞功能中的应用。 (PCT/CN2015/084078) WO/2016/011906A1

发明人：李斌 (LI, Bin), 杨静 (YANG, Jing), 韩磊 (HAN, Lei) ,林芳(LIN, Fang), 李孔晨 (LI, Kongchen), 李丹 (LI, Dan)

 4. 泛素化途径相关因子在调控调节性T细胞功能中的应用 （CN108144049A）

发明人：李斌;杨静;徐鹏;李丹;梁瑞